Trial Profile
Multicenter, Prospectively Defined Observational Registry With Retrospective Data Collection, Evaluating Premature and Term-Near-Term Neonates With Pulmonary Hypertension Receiving Inhaled Nitric Oxide Via Invasive or Noninvasive Ventilation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PaTTerN
- Sponsors Mallinckrodt Inc.
- 30 Apr 2021 Results published in the Media Release
- 30 Apr 2021 According to a Mallinckrodt Pharmaceuticals media release, data from this study will be presented at the The Pediatric Academic Societies (PAS) 2021 Virtual Meeting.
- 04 May 2020 According to a Mallinckrodt Pharmaceuticals media release, the company will share the results of this study in an appropriate scientific forum soon.